Ramírez-Bonilla M, González-Cuenca E, Castillejos-Molina R, Sotomayor-de Zavaleta M, Gabilondo-Navarro F, Feria-Bernal G, Rodríguez-Covarrubias F

Language: Spanish
References: 11
Page: 235-239
PDF size: 100.96 Kb.

ABSTRACT

Background: Seminoma treatment, in addition to orchiectomy (ORC) includes: surveillance, chemotherapy (CT), and radiotherapy (RT), depending on the clinical stage of the disease.
Aims: To report the progression of patients presenting with seminoma that were treated in our hospital.
Methods: A total of 60 cases were analyzed. The variables were age, tumor markers (TM), pathologic stage, and lymphovascular invasion (LVI). Follow-up was carried out with TM and imaging studies. Overall survival (OS) and recurrence-free survival (RFS) were evaluated.
Results: The mean age was 32.8 years. The beta-subunit of human chorionic gonadotropin (βhCG) and lactate dehydrogenase (LDH) were elevated in 28.3% and 20% of the cases, respectively. The most common stage was IA (41.6%), followed by IB (26.6%). A total of 26.7% cases presented with LVI. The mean follow-up period was 68 months. Treatment after ORC was: surveillance in 15 cases, CT in 24, RT in 18, and CT followed by ORC in 3 cases. RFS at 10 to 15 years was 80% and 71%, respectively. Within the same time frame, OS was 100%. Two deaths from tumors other than testicular cancer were reported.
Conclusions: Seminoma management should be multidisciplinary, with a strict long-term follow-up. Even though disease outcome is good, there is the possibility of death from secondary tumors.

REFERENCES

1. Consultado el 01 de octubre de 2012. http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/CI5vol9-A.pdf.

2. Consultado el 20 de septiembre de 2012. http://globocan.iarc.fr/

3. Osterlid A, Bertheisen JG, Abidagaard N, et al. Risk of bilateral testicular germ cell tumors in Denmark; 1960-1984. J Natl Cancer Inst 1991;83(19):1391-1395.

4. WHO histological classification of testis tumours. In: Eble JN, Sauter G, Epstein JI, et al (editors). Pathology & Genetics. Tumors of the urinary system and male genital organs. Lyons. IARC Press. 2004. 250-262.

5. Huyghe E, Matusda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170(1):5-11.

6. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15(2):594-603.

7. Sternberg CN. The management of stage I testis cancer. Urol Clin North Am 1998;25(3):435-449.

8. Javadpour N. The role of biologic markers in testicular cancer. Cancer 1980;45(7Suppl):1755-1761.

9. Sternberg CN. The management of stage I testis cancer. Urol Clin North Am 1998;25(3):435-449.

10. Aparicio J, García-del Muro X, Maroto P, et al. Spanish Germ Cell Cancer Cooperative Group (GG). Multicenter study evaluating a dual policy of postorchidectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003;14(6):867-872.

11. García-del Muro X, Maroto P, Guma J, et al. Chemotherapy as an alternative to radiotherapy in the treatmentof stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008;26(33):5416-5421.